AMIODARONE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

AMIODARONE HYDROCHLORIDE

から入手可能:

SIVEM PHARMACEUTICALS ULC

ATCコード:

C01BD01

INN（国際名）:

AMIODARONE

投薬量:

200MG

医薬品形態:

TABLET

構図:

AMIODARONE HYDROCHLORIDE 200MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

CLASS III ANTIARRYTHMICS

製品概要:

Active ingredient group (AIG) number: 0118593001; AHFS:

認証ステータス:

APPROVED

承認日:

2012-05-31

製品の特徴

_ _
_Amiodarone _
_Page 1 of 65_
_ _
_ _
PRODUCT MONOGRPAH
PR
AMIODARONE
Amiodarone Hydrochloride tablets, BP
200 mg
Antiarrhythmic Agent
SIVEM PHARMACEUTICALS ULC
Date of Revision:
4705 Dobrin Street
October 27, 2016
St. Laurent, Quebec
H4R 2P7
www.sivem.ca
Control number: 198891
_ _
_Amiodarone _
_Page 2 of 65_
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS
.......................................................................................................................................
19
DRUG
INTERACTIONS........................................................................................................................................
23
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
28
OVERDOSAGE
......................................................................................................................................................
30
ACTION
AND
CLINICAL
PHARMACOLOGY
...................................................................................................
31
STORAGE
AND
STABILITY
................................................................................................................................
34
SPECIAL
HANDLING
INSTRUCTIONS
....................................